We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas.
- Authors
Staudacher, J. J.; Arnold, Alexander; Kühl, A. A.; Pötzsch, M.; Daum, S.; Winterfeld, M.; Berg, E.; Hummel, M.; Rau, B.; Stein, U.; Treese, C.
- Abstract
<bold>Purpose: </bold>Adenocarcinomas of the esophagus (AEG) and stomach (AS) are among the most common cancers worldwide. Novel markers for risk stratification and guiding treatment are strongly needed. Activin is a multi-functional cytokine with context specific pro- and anti-tumorigenic effects. We aimed to investigate the prognostic role of activin tumor protein expression in AEG/ASs.<bold>Methods: </bold>Tissue from a retrospective cohort of 277 patients with AEG/AS treated primarily by surgery at the Charité - Universitätsmedizin Berlin was collected and analyzed by immunohistochemistry using a specific antibody to the activin homodimer inhibin beta A. Additionally, we evaluated T-cell infiltration and PD1 expression as well as expression of PD-L1 by immunohistochemistry as possible confounding factors. Clinico-pathologic data were collected and correlated with activin protein expression.<bold>Results: </bold>Out of 277 tumor samples, 72 (26.0%) exhibited high activin subunit inhibin beta A protein expression. Higher expression was correlated with lower Union for International Cancer Control (UICC) stage and longer overall survival. Interestingly, activin subunit expression correlated with CD4+ T-cell infiltration, and the correlation with higher overall survival was exclusively seen in tumors with high CD4+ T-cell infiltration, pointing towards a role of activin in the tumor immune response in AEG/ASs.<bold>Conclusion: </bold>In our cohort of AEG/AS, higher activin subunit levels were correlated with longer overall survival, an effect exclusively seen in tumors with high CD4+ cell infiltration. Further mechanistic research is warranted discerning the exact effect of this context specific cytokine.
- Subjects
ALLGEMEINE Elektricitats-Gesellschaft AG; INHIBIN; ACTIVIN; ADENOCARCINOMA; TUMOR proteins; ESOPHAGEAL cancer; PROTEIN expression
- Publication
BMC Cancer, 2022, Vol 22, Issue 1, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-022-10016-5